RT info:eu-repo/semantics/article
T1 Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials
A1 Labrador Velandia, Sonia Cecilia
A1 Alonso Alonso, María Luz
A1 Álvarez Sánchez, Sara
A1 González Zamora, Jorge
A1 Pastor Jimeno, José Carlos
A1 Fernández Bueno, Iván
A1 Srivastava, Girish Kumar
K1 Células madre
K1 Retina
AB Retinal and optic nerve diseases are degenerative ocular pathologies which lead to irreversible visual loss. Since the advanced therapies availability, cell-based therapies offer a new all-encompassing approach. Advances in the knowledge of neuroprotection, immunomodulation and regenerative properties of mesenchymal stem cells (MSCs) have been obtained by several preclinical studies of various neurodegenerative diseases. It has provided the opportunity to perform the translation of this knowledge to prospective treatment approaches for clinical practice. Since 2008, several first steps projecting new treatment approaches, have been taken regarding the use of cell therapy in patients with neurodegenerative pathologies of optic nerve and retina. Most of the clinical trials usingMSCs are in Ⅰ/Ⅱ phase, recruiting patients or ongoing, and they have as main objective the safety assessment of MSCs using various routes of administration. However, it is important to recognize that, there is still a long way to go to reach clinical trials phase Ⅲ-Ⅳ. Hence, it is necessary to continue preclinical and clinical studies to improve this new therapeutic tool. This paper reviews the latest progress of MSCs in human clinical trials for retinal and optic nerve diseases
PB Baishideng Publishing Group
SN 1948-0210
YR 2016
FD 2016
LK http://uvadoc.uva.es/handle/10324/21595
UL http://uvadoc.uva.es/handle/10324/21595
LA eng
NO World Journal of Stem Cells  2016, 26; 8(11), p. 376-383
NO Producción Científica
DS UVaDOC
RD 27-abr-2024